ANIK Key Statistics, Chart & Performance
The current stock price of ANIK is 9.35 USD. In the past month the price decreased by -1.27%. In the past year, price decreased by -42.25%.
ANIK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About ANIK
Company Profile
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 288 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Company Info
ANIKA THERAPEUTICS INC
32 Wiggins Ave
Bedford MASSACHUSETTS 01730 US
CEO: Cheryl R. Blanchard
Employees: 288
Phone: 17814579000
ANIKA THERAPEUTICS INC / ANIK FAQ
What does ANIK do?
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 288 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
What is the stock price of ANIKA THERAPEUTICS INC today?
The current stock price of ANIK is 9.35 USD. The price decreased by -2.71% in the last trading session.
What is the dividend status of ANIKA THERAPEUTICS INC?
ANIK does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANIK stock?
ANIK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the PE ratio for ANIK stock?
ANIKA THERAPEUTICS INC (ANIK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.28).
Should I buy ANIK stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ANIK.
How many employees does ANIKA THERAPEUTICS INC have?
ANIKA THERAPEUTICS INC (ANIK) currently has 288 employees.
ANIK Technical Analysis
ANIK Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ANIK. ANIK has a great financial health rating, but its profitability evaluates not so good.
ANIK Financial Highlights
Over the last trailing twelve months ANIK reported a non-GAAP Earnings per Share(EPS) of -2.28. The EPS increased by 53.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.3% | ||
| ROE | -41.05% | ||
| Debt/Equity | 0 |
ANIK Forecast & Estimates
8 analysts have analysed ANIK and the average price target is 16.32 USD. This implies a price increase of 74.55% is expected in the next year compared to the current price of 9.35.
For the next year, analysts expect an EPS growth of 46.29% and a revenue growth -26.08% for ANIK